SUPN
Supernus Pharmaceuticals, Inc.
Drug Manufacturers - Specialty & Generic · Healthcare · United States
47.15
close · 2026-08-13
value
48
cheaper than peers48
quality
77
stronger fundamentals77
ranked against
Drug Manufacturers - Specialty & Generic
value
quality
34 peerswide variation
Value inputs
| measure | company | vs peers |
| price to book | 2.66× | 67 |
| forward P/E | 10.57× | 61 |
| price to sales | 3.44× | 37 |
| EV to EBITDA | 18.32× | 37 |
4 of 12 measures available
Quality inputs
| measure | company | vs peers |
| debt to equity | 3.8% | 95 |
| revenue growth | 38.6% | 86 |
| return on equity | -2.8% | 43 |
| operating margin | -3.6% | 31 |
4 of 4 measures available
Facts
| market cap | $3B |
| free cash flow | $132.6M |
| employees | 778 |
| first trade | 2012-05-01 |
| next earnings | 2026-08-03 |
| fundamentals updated | 2026-08-03 |